Skip to main content
SpringerLink
Log in

Adjuvant Chemotherapy May Not Be Necessary for Women with Stage IC1 Epithelial Ovarian Cancer

  • Published:
Current Medical Science Aims and scope Submit manuscript

Abstract

Objective

To determine whether adjuvant chemotherapy improves the prognoses in women with stage IC1 epithelial ovarian cancer (EOC).

Methods

All eligible women diagnosed with stage IC1 EOC from 2003 to 2019 in Tongji Hospital were included. Patient characteristics, tumor features, surgical types, and chemotherapeutic treatments were collected. Kaplan-Meier analysis and Cox regression analysis were performed to evaluate progression-free survival (PFS) and overall survival (OS).

Results

Of the 140 patients (median age: 47 years old), 13 patients did not receive chemotherapy, and 127 received adjuvant chemotherapy. Kaplan-Meier analysis indicated that adjuvant chemotherapy offered no obvious improvements in PFS or OS. Subgroup analysis was conducted to adjust for the significant difference in incomplete staging surgery between the two groups, and chemotherapy still showed no benefit for survival. Cox regression analysis indicated that incomplete staging surgery was a risk factor for a worse PFS and that adjuvant chemotherapy remained unrelated to the prognosis. The patients were further divided based on the National Comprehensive Cancer Network recommendations: patients for whom observation is optional and chemotherapy would not improve the prognosis; and patients for whom chemotherapy is recommended. The results showed that postoperative chemotherapy had little correlation with survival.

Conclusion

Our study suggests that postoperative chemotherapy may be unnecessary for patients with stage IC1 EOC. According to our results, incomplete staging surgery is a significant risk factor for PFS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin, 2019,69(1):7–34

    Article  Google Scholar 

  2. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer. NCCN Clinical Practice Guidelines in oncology (NCCN Guidelines). https://www.nccn.org/.2019

  3. Childress KJ, Santos XM, Perez-Milicua G, et al. Intraoperative Rupture of Ovarian Dermoid Cysts in the Pediatric and Adolescent Population: Should This Change Your Surgical Management? J Pediatr Adolesc Gynecol, 2017,30(6):636–640

    Article  Google Scholar 

  4. Fauvet R, Boccara J, Dufournet C, et al. Laparoscopic management of borderline ovarian tumors: results of a French multicenter study. Ann Oncol, 2005,16(3):403–410

    Article  CAS  Google Scholar 

  5. Iglesias DA, Ramirez PT. Role of minimally invasive surgery in staging of ovarian cancer. Curr Treat Options Oncol, 2011,12(3):217–229

    Article  Google Scholar 

  6. Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet, 2014,124(1):1–5

    Article  Google Scholar 

  7. Bakkum-Gamez JN, Richardson DL, Seamon LG, et al. Influence of intraoperative capsule rupture on outcomes in stage I epithelial ovarian cancer. Obstet Gynecol, 2009,113(1):11–17

    Article  Google Scholar 

  8. Vergote I, De Brabanter J, Fyles A, et al. Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet, 2001,357(9251):176–182

    Article  CAS  Google Scholar 

  9. Tang H, Liu Y, Wang X, et al. Clear cell carcinoma of the ovary: Clinicopathologic features and outcomes in a Chinese cohort. Medicine (Baltimore), 2018,97(21):e10881

    Article  CAS  Google Scholar 

  10. Matsuo K, Machida H, Yamagami W, et al. Intraoperative Capsule Rupture, Postoperative Chemotherapy, and Survival of Women With Stage I Epithelial Ovarian Cancer. Obstet Gynecol, 2019,134(5):1017–1026

    Article  Google Scholar 

  11. Kajiyama H, Suzuki S, Yoshikawa N, et al. Survival impact of capsule status in stage I ovarian mucinous carcinoma-A mulicentric retrospective study. Eur J Obstet Gynecol Reprod Biol, 2019,234:131–136

    Article  Google Scholar 

  12. Matsuo K, Huang Y, Zivanovic O, et al. Effectiveness of postoperative chemotherapy for stage IC mucinous ovarian cancer. Gynecol Oncol, 2019,154(3):505–515

    Article  CAS  Google Scholar 

  13. Shimizu D, Sato N, Sato T, et al. Impact of adjuvant chemotherapy for stage I ovarian carcinoma with intraoperative tumor capsule rupture. J Obstet Gynaecol Res, 2015,41(3):432–439

    Article  Google Scholar 

  14. Suh DH, Park JY, Lee JY, et al. The clinical value of surgeons’ efforts of preventing intraoperative tumor rupture in stage I clear cell carcinoma of the ovary: A Korean multicenter study. Gynecol Oncol, 2015,137(3):412–417

    Article  Google Scholar 

  15. Le T, Adolph A, Krepart GV, et al. The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol, 2002,85(2):351–355

    Article  Google Scholar 

  16. Tu H, Xiong Y, Huang H, et al. Individualized Treatment of Patients with Early-Stage Epithelial Ovarian Cancer After Incomplete Initial Surgery. Int J Gynecol Cancer, 2016,26(1):73–81

    Article  Google Scholar 

  17. Ayhan A, Gultekin M, Celik NY, et al. Occult metastasis in early ovarian cancers: risk factors and associated prognosis. Am J Obstet Gynecol, 2007,196(1):81.e1–6

    Article  Google Scholar 

Download references

Author information

Author notes

  1. Dong-mei DENG and Qiu-yue LIAO contributed equally to this work.

Authors and Affiliations

  1. Department of Gynecology and Obstetrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

    Dong-mei Deng, Qiu-yue Liao, Jie Yang, Jing Chen, Ge Chen, Hua-lin Bai, Bo Zhang & Ke-zhen Li

Authors
  1. Dong-mei Deng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qiu-yue Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jie Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jing Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ge Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hua-lin Bai
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bo Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ke-zhen Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Bo Zhang or Ke-zhen Li.

Ethics declarations

The authors have no conflicts of interest.

Additional information

This study was supported by grants from the National Key Technology R&D Program of China (No. 2019YFC1005200, No. 2019YFC1005202 and 2018YFC1002103) and the National Natural Science Foundation of China (No. 81802896).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Deng, Dm., Liao, Qy., Yang, J. et al. Adjuvant Chemotherapy May Not Be Necessary for Women with Stage IC1 Epithelial Ovarian Cancer. CURR MED SCI 42, 192–200 (2022). https://doi.org/10.1007/s11596-021-2462-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11596-021-2462-7

Key words

Search

Navigation